{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:25:40Z","timestamp":1790900740417,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"S2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. This review summarizes some of the immunological effects of GM-CSF relevant to antitumor immunity in cancer patients. GM-CSF has been used to augment the activity of rituximab in patients with follicular lymphoma and to induce autologous antitumor immunity in patients with hormone-refractory prostate cancer. GM-CSF causes upregulation of costimulatory molecule expression on leukemia blasts in vitro, enhancing their ability to present antigen to allogeneic T cells, and, in combination with interferon-\u03b1, can induce antitumor immune responses in patients whose acute leukemia has relapsed following allogeneic hematopoietic progenitor cell transplant. Tumor cells engineered to secrete GM-CSF are particularly effective as antitumor vaccines, and the addition of GM-CSF to standard vaccines may increase their effectiveness by recruiting DCs to the site of vaccination. However, a significant limitation in the use of GM-CSF as an immunostimulatory agent is that objective antitumor responses are infrequent, and are often not durable. Effective and durable antitumor immunity will likely require novel methods to eliminate counterregulatory immune responses that limit activation and expansion of cytotoxic T cells with antitumor activity.<\/jats:p>","DOI":"10.1634\/theoncologist.12-s2-22","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T11:25:42Z","timestamp":1581333942000},"page":"22-26","source":"Crossref","is-referenced-by-count":46,"title":["The Role of Sargramostim (rhGM-CSF) as Immunotherapy"],"prefix":"10.1093","volume":"12","author":[{"given":"Edmund K.","family":"Waller","sequence":"first","affiliation":[{"name":"Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"2021122208463799300_R1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bbmt.2004.07.008","article-title":"A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products","volume":"10","author":"Lonial","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122208463799300_R2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/sj.leu.2401685","article-title":"Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells","volume":"14","author":"Boyer","year":"2000","journal-title":"Leukemia"},{"key":"2021122208463799300_R3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2006.09.005","article-title":"Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience","volume":"13","author":"Arellano","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122208463799300_R4","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2004.09.106","article-title":"Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials","volume":"22","author":"Sung","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2006.07.1753","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1317::AID-CNCR7>3.0.CO;2-X","article-title":"Granulocyte-macrophagecolony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: Results of two phase II clinical trials","volume":"88","author":"Ryan","year":"2000","journal-title":"Cancer"},{"key":"2021122208463799300_R7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002371-200105000-00010","article-title":"Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial","volume":"24","author":"Schmidinger","year":"2001","journal-title":"J Immunother"},{"key":"2021122208463799300_R8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.bjc.6600915","article-title":"Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma","volume":"88","author":"Verra","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122208463799300_R9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.cji.0000177998.57713.c9","article-title":"A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma","volume":"28","author":"Koulova","year":"2005","journal-title":"J Immunother"},{"key":"2021122208463799300_R10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00002371-200307000-00009","article-title":"Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase 2 trial of the Cancer Biotherapy Research Group","volume":"26","author":"Dillman","year":"2003","journal-title":"J Immunother"},{"key":"2021122208463799300_R11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-199501000-00007","article-title":"A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell carcinoma","volume":"17","author":"O'Donnell","year":"1995","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"2021122208463799300_R12","first-page":"73","article-title":"Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients","volume":"17","author":"Lissoni","year":"2003","journal-title":"In Vivo"},{"key":"2021122208463799300_R13","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122208463799300_R14","first-page":"951","article-title":"Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"86","author":"Sacchi","year":"2001","journal-title":"Haematologica"},{"key":"2021122208463799300_R15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1046\/j.1365-2141.2002.03535.x","article-title":"Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma","volume":"117","author":"Friedberg","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122208463799300_R16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"Ansell","year":"2002","journal-title":"Blood"},{"key":"2021122208463799300_R17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2402995","article-title":"Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy","volume":"17","author":"van der Kolk","year":"2003","journal-title":"Leukemia"},{"issue":"suppl 5","key":"2021122208463799300_R18","first-page":"v68","article-title":"Rituximab plus GM-CSF (Leukine\u00ae) for indolent lymphoma [abstract]","volume":"16","author":"McLaughlin","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122208463799300_R19","doi-asserted-by":"crossref","first-page":"684a","DOI":"10.1182\/blood.V106.11.2432.2432","article-title":"Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma: Results of a phase II study [abstract]","volume":"106","author":"Rossi","year":"2005","journal-title":"Blood"},{"key":"2021122208463799300_R20","first-page":"1738","article-title":"Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor","volume":"5","author":"Small","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122208463799300_R21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1200\/JCO.2003.04.163","article-title":"Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer","volume":"21","author":"Rini","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R22","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0022-5347(06)00261-8","article-title":"Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor","volume":"175","author":"Rini","year":"2006","journal-title":"J Urol"},{"key":"2021122208463799300_R23","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1200\/JCO.2002.01.151","article-title":"Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine","volume":"20","author":"Hsueh","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R24","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2003.10.005","article-title":"Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells","volume":"21","author":"Slingluff","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cncr.11045","article-title":"Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma","volume":"97","author":"Weber","year":"2003","journal-title":"Cancer"},{"key":"2021122208463799300_R26","first-page":"952","article-title":"Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor","volume":"7","author":"Rakhmilevich","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122208463799300_R27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nat Med"},{"key":"2021122208463799300_R28","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma\u2014a feasibility study","volume":"93","author":"Reichardt","year":"1999","journal-title":"Blood"},{"key":"2021122208463799300_R29","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1073\/pnas.141226398","article-title":"Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy","volume":"98","author":"Fong","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208463799300_R30","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R31","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitorderived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"2021122208463799300_R32","doi-asserted-by":"crossref","first-page":"8978","DOI":"10.1200\/JCO.2005.01.6816","article-title":"Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF\u2013transduced tumor cells in metastatic melanoma patients","volume":"23","author":"Luiten","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208463799300_R33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01.cji.0000211309.90621.8b","article-title":"Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity","volume":"29","author":"Palucka","year":"2006","journal-title":"J Immunother"},{"key":"2021122208463799300_R34","volume-title":"Vaccine Therapy and\/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma","year":"2007"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-S2-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-S2-22","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/S2\/22\/41835631\/oncolo_12_s2_22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/S2\/22\/41835631\/oncolo_12_s2_22.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:34:02Z","timestamp":1640187242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/S2\/22\/6395789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":34,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2007,10,1]]},"published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-s2-22","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,10,1]]},"published":{"date-parts":[[2007,10,1]]}}}